These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

792 related articles for article (PubMed ID: 25840462)

  • 1. Amyloid biomarkers in Alzheimer's disease.
    Blennow K; Mattsson N; Schöll M; Hansson O; Zetterberg H
    Trends Pharmacol Sci; 2015 May; 36(5):297-309. PubMed ID: 25840462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
    Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
    J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reference measurement procedure for CSF amyloid beta (Aβ)
    Pannee J; Portelius E; Minthon L; Gobom J; Andreasson U; Zetterberg H; Hansson O; Blennow K
    J Neurochem; 2016 Nov; 139(4):651-658. PubMed ID: 27579672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
    Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.
    Lewczuk P; Matzen A; Blennow K; Parnetti L; Molinuevo JL; Eusebi P; Kornhuber J; Morris JC; Fagan AM
    J Alzheimers Dis; 2017; 55(2):813-822. PubMed ID: 27792012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review.
    Brand AL; Lawler PE; Bollinger JG; Li Y; Schindler SE; Li M; Lopez S; Ovod V; Nakamura A; Shaw LM; Zetterberg H; Hansson O; Bateman RJ
    Alzheimers Res Ther; 2022 Dec; 14(1):195. PubMed ID: 36575454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease.
    Cohen AD; Landau SM; Snitz BE; Klunk WE; Blennow K; Zetterberg H
    Mol Cell Neurosci; 2019 Jun; 97():3-17. PubMed ID: 30537535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards the Integrative Theory of Alzheimer's Disease: Linking Molecular Mechanisms of Neurotoxicity, Beta-amyloid Biomarkers, and the Diagnosis.
    Molkov YI; Zaretskaia MV; Zaretsky DV
    Curr Alzheimer Res; 2023; 20(6):440-452. PubMed ID: 37605411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography.
    Palmqvist S; Mattsson N; Hansson O;
    Brain; 2016 Apr; 139(Pt 4):1226-36. PubMed ID: 26936941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on biomarkers for amyloid pathology in Alzheimer's disease.
    Ashton NJ; Schöll M; Heurling K; Gkanatsiou E; Portelius E; Höglund K; Brinkmalm G; Hye A; Blennow K; Zetterberg H
    Biomark Med; 2018 Jul; 12(7):799-812. PubMed ID: 29902934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid-β PET-Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic.
    Müller EG; Edwin TH; Stokke C; Navelsaker SS; Babovic A; Bogdanovic N; Knapskog AB; Revheim ME
    PLoS One; 2019; 14(8):e0221365. PubMed ID: 31430334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment.
    Nordberg A; Kadir A; Andreasen N; Almkvist O; Wall A; Långström B; Zetterberg H
    J Alzheimers Dis; 2015; 47(3):691-704. PubMed ID: 26401704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Defining and disease-modifying therapy for the preclinical stages of Alzheimer's disease].
    Sakurai H; Hanyu H
    Nihon Rinsho; 2016 Mar; 74(3):438-41. PubMed ID: 27025083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease.
    Andreasen N; Blennow K
    Peptides; 2002 Jul; 23(7):1205-14. PubMed ID: 12128078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration.
    Rogeberg M; Almdahl IS; Wettergreen M; Nilsson LN; Fladby T
    J Proteome Res; 2015 Nov; 14(11):4834-43. PubMed ID: 26452689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection and quantification of Aβ-3-40 (APP669-711) in cerebrospinal fluid.
    Klafki HW; Wirths O; Mollenhauer B; Liepold T; Rieper P; Esselmann H; Vogelgsang J; Wiltfang J; Jahn O
    J Neurochem; 2022 Mar; 160(5):578-589. PubMed ID: 34984682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial.
    Wang T; Huang Q; Reiman EM; Chen K; Li X; Li G; Lin Z; Li C; Xiao S
    J Clin Psychopharmacol; 2013 Oct; 33(5):636-42. PubMed ID: 23948786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.